Status:
COMPLETED
Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita
Lead Sponsor:
Pachyonychia Congenita Project
Conditions:
Pachyonychia Congenita
Eligibility:
All Genders
10+ years
Phase:
PHASE1
Brief Summary
Pachyonychia congenita (PC) is a rare, autosomal dominant keratin disorder affecting the nails, skin, oral mucosae, larynx, hair and teeth. Pathogenic mutations in keratin K6a, K6b, K16 or K17 act via...
Eligibility Criteria
Inclusion
- A positive genetic identification of the N171K mutation in the keratin 6a gene from a CLIA certified laboratory;
- Witnessed, signed informed consent approved by Institutional Review Board/Ethics Committee;
- A signed Health Information Portability and Accountability Act (HIPAA) authorization form which permits the use and disclosure of patient's individually identifiable health information for those enrolled in the United States of America;
- Male or female subjects of any race 10 years of age and older;
- Complete physical examination and medical history indicating no abnormalities that will interfere with study objectives;
- Normal or not clinically significant baseline laboratory tests, including hemogram, ANA, serum chemistry panel, urinalysis, C3a, Bb, and APTT,PT;
- Negative pregnancy test (females only).
Exclusion
- Females of childbearing potential not using a highly effective method of birth control (e.g. implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices) during the study;
- Diabetes mellitus requiring treatment other than diet and exercise;
- Treatment of any type for cancer within the last six months;
- History of any significant internal disease;
- Subjects who are known to be allergic to any of the test product(s) or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations;
- History of street drug or alcohol abuse;
- Any patient not able to meet the study attendance requirements;
- Subjects who have participated in any other trial of an investigational drug or device within 60 days prior to enrollment or participation in a research study concurrent with this study.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2008
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00716014
Start Date
January 1 2008
End Date
August 1 2008
Last Update
November 19 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112